FDA clarifies DES reports
This article was originally published in The Gray Sheet
Executive Summary
Updated 1public health notification on J&J/Cordis' Cypher drug-eluting stent, issued by FDA Nov. 25, follows reports from physicians and Cordis reps maintaining that an earlier, Oct. 10 notice misled the public about safety concerns related to thrombosis and hypersensitivity (2"The Gray Sheet" Nov. 3, 2003, p. 4). "We consider the Cypher stent a safe and effective product when used according to the labeling, particularly concerning patient selection and appropriate peri-procedural medication," FDA clarifies...
You may also be interested in...
Thrombosis Events May Be Clarified By e-CYPHER Data Expected In February
FDA's public health notification related to adverse events for J&J/Cordis' Cypher is intended to generate further data collection for the drug-eluting stent rather than raise undue concern over clotting issues, the agency says
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.